The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results of the dose-finding phase of ARST 1321 from the Children's Oncology Group and NRG Oncology: Neoadjuvant chemoradiation or radiation therapy +/- pazopanib in non-rhabdomyosarcoma soft tissue sarcomas.
 
Yen-Lin Chen
No Relationships to Disclose
 
Aaron R. Weiss
No Relationships to Disclose
 
Thomas Scharschmidt
No Relationships to Disclose
 
Yueh-Yun Chi
No Relationships to Disclose
 
Jennifer M. Black
No Relationships to Disclose
 
Edwin Choy
Consulting or Advisory Role - Immune Design
Research Funding - Amgen (Inst); AstraZeneca (Inst); Exelixis (Inst); Immune Design (Inst); Iterion Therapeutics (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst)
 
Simon C. Kao
No Relationships to Disclose
 
Mark Kayton
No Relationships to Disclose
 
Scott H. Okuno
No Relationships to Disclose
 
Andrew Ostrenga
No Relationships to Disclose
 
R Randall
No Relationships to Disclose
 
Stephanie Alicia Terezakis
No Relationships to Disclose
 
Eduardo Zambrano
No Relationships to Disclose
 
Sheri L. Spunt
Research Funding - Loxo (Inst)
 
Douglas S. Hawkins
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Celgene; Loxo
 
Dian Wang
No Relationships to Disclose